<DOC>
	<DOCNO>NCT00412880</DOCNO>
	<brief_summary>Open label , uncontrolled Phase II trial ass efficacy safety BI 2536 second line treatment sensitive-relapse SCLC patient .</brief_summary>
	<brief_title>BI 2536 Second Line Monotherapy SCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<criteria>Patients histologically cytologically confirm , sensitiverelapse SCLC define relapse 60 day cessation prior firstline chemotherapy . Patients least one measurable lesion , long diameter record 20 mm great . Life expectancy least three month ECOG performance score 2 less write informed consent must consistent ICHGCP Guidelines . More one prior regimen chemotherapy , mixed small cell/large cell combine small cell histology . Symptomatic brain metastasis leptomenigeal disease Patients ascites , patient lifethreatening illness organ system dysfunction , malignancy diagnose within past five ( 5 ) year ( non melanomatous skin cancer ) Absolute neutrophil count ( ANC ) &lt; 1,500/µl , platelet count &lt; 100,000/µl , hemoglobin &lt; 9 mg/dl Total bilirubin &gt; 1.5 x ULN , aspartame amino transferase ( AST ) and/or alanine amino transferase ( ALT ) &gt; 2.5 x ULN , aspartate amino transferase ( AST ) and/or alanine amino transferase ( ALT ) &gt; 5 x ULN case know liver metastasis , serum creatinine &gt; 2.0 mg/dl ( &gt; 176 µmol/L , SI Unit equivalent ) Chemo , hormone ( Megace® ) immunotherapy within past 4 week within less 4 halflife time previous drug prior treatment trial drug Radiation therapy within past 2 week prior treatment trial drug Patients serious active infection ( i.e. , require IV antibiotic , antifungal , antiviral agent ) , patient know HIV , hepatitisB C infection Known suspect active drug alcohol abuse Treatment investigational drug within past 4 week within less 4 halflife time investigational drug Patients know preexist coagulopathy require therapeutic anticoagulation warfarin ( Coumadin ® ) Patients neuropathy ( sensory motor ) CTCAE 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>